|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 656.01 USD | +0.63% |
|
-3.06% | -15.01% |
| 25/07 | US FDA approves Outlook Therapeutics' eye disease drug | RE |
| 24/07 | Sanofi to Drop Eczema Drug Amid Review of Pipeline Under New CEO | DJ |
| Market Cap | 6.67TCr 5.86TCr 5.45TCr 5TCr 9.4TCr 6,42700Cr 9.54TCr 65TCr 25TCr 3,16000Cr 25TCr 25TCr 10,92500Cr | P/E 2026 * |
17.3x | P/E 2027 * | 13.8x |
|---|---|---|---|---|---|
| Enterprise Value | 5.89TCr 5.17TCr 4.81TCr 4.42TCr 8.3TCr 5,67400Cr 8.43TCr 57TCr 22TCr 2,79000Cr 22TCr 22TCr 9,64500Cr | EV / Sales 2026 * |
3.71x | EV / Sales 2027 * | 3.19x |
| Free-Float |
72.33% | Yield 2026 * |
0.59% | Yield 2027 * | 0.67% |
Last Transcript: Regeneron Pharmaceuticals, Inc.
| 1 day | +0.63% | ||
| 1 week | -3.06% | ||
| Current month | +5.21% | ||
| 1 month | +5.23% | ||
| 3 months | -12.71% | ||
| 6 months | -12.94% | ||
| Current year | -15.01% |
| 1 week | 637.8 |  | 681.74 |
| 1 month | 622.29 | | 691.13 |
| Current year | 591.52 | | 821.11 |
| 1 year | 541 | | 821.11 |
| 3 years | 476.49 | | 1,211.2 |
| 5 years | 476.49 | | 1,211.2 |
| 10 years | 271.37 | | 1,211.2 |
| Manager | Title | Age | Since |
|---|---|---|---|
| President | 66 | 01/01/2001 | |
| Chief Executive Officer | 73 | 08/01/1988 | |
| Director of Finance/CFO | 55 | 05/02/2024 |
| Director | Title | Age | Since |
|---|---|---|---|
| Chairman | 73 | 09/06/2023 | |
Michael Brown
BRD | Director/Board Member | 85 | 01/06/1991 |
Joseph Goldstein
BRD | Director/Board Member | 85 | 01/06/1991 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 02/07/26 | Sell | Director | -200 | 0.0002% | ||
| 01/05/26 | Sell | Director | -100 | 0.0001% | ||
| 01/04/26 | Sell | Director | 100 | 0.0001% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.63% | -3.06% | +16.18% | -9.78% | 6.67TCr | |
| +1.23% | +2.80% | +37.51% | +202.14% | 5.33TCr | |
| +10.08% | +51.80% | +51.80% | +51.80% | 4.81TCr | |
| -1.32% | -7.38% | -57.63% | -57.10% | 3.83TCr | |
| +0.78% | -1.84% | +52.49% | -27.01% | 2.99TCr | |
| +0.84% | +0.36% | +66.93% | +85.42% | 2.35TCr | |
| -5.17% | -12.54% | +58.98% | -56.04% | 2.15TCr | |
| -1.21% | +1.12% | +1.98% | +170.93% | 2TCr | |
| -0.22% | -0.95% | +61.97% | +123.78% | 1.64TCr | |
| +1.31% | +3.24% | +84.01% | +152.77% | 1.65TCr | |
| Average | +1.29% | -0.57% | +37.42% | +63.69% | 3.34TCr | |
| Weighted average by Cap. | +1.78% | +0.06% | +30.57% | +55.05% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 1.59TCr 1.39TCr 1.3TCr 1.19TCr 2.24TCr 1,52900Cr 2.27TCr 15TCr 6.01TCr 75TCr 5.96TCr 5.83TCr 2,59800Cr | 1.76TCr 1.55TCr 1.44TCr 1.32TCr 2.48TCr 1,69600Cr 2.52TCr 17TCr 6.67TCr 83TCr 6.61TCr 6.47TCr 2,88200Cr |
| Net income | 397.65Cr 349.26Cr 324.8Cr 298.05Cr 560.01Cr 38TCr 568.64Cr 3.86TCr 1.51TCr 19TCr 1.49TCr 1.46TCr 65TCr | 502.53Cr 441.38Cr 410.47Cr 376.66Cr 707.71Cr 48TCr 718.62Cr 4.87TCr 1.9TCr 24TCr 1.89TCr 1.85TCr 82TCr |
| Net Debt | -782.28Cr -687.08Cr -638.97Cr -586.33Cr -1.1TCr -75TCr -1.12TCr -7.59TCr -2.96TCr -37TCr -2.94TCr -2.87TCr -1,28100Cr | -1.05TCr -923.35Cr -858.7Cr -787.97Cr -1.48TCr -1,01200Cr -1.5TCr -10TCr -3.98TCr -50TCr -3.95TCr -3.86TCr -1,72100Cr |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24/26/24 | $656.01 | +0.63% | 7,08,392 |
| 23/26/23 | $651.91 | +0.11% | 11,29,411 |
| 22/26/22 | $651.18 | -3.56% | 8,72,170 |
| 21/26/21 | $675.19 | +0.45% | 5,29,783 |
| 20/26/20 | $672.15 | -0.67% | 6,24,791 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- REGN Stock
Select your edition
All financial news and data tailored to specific country editions
